1. Combined programmed cell death protein 1 and cytotoxic T-lymphocyte associated protein 4 blockade in an international cohort of patients with acral lentiginous melanoma.
- Author
-
McGillivray E, Ashouri K, Chatziioannou E, Gallegos JAO, Zarka J, Kechter J, Hwang AS, Zhang K, Barros M, Yeh J, Okazaki I, Crocker AB, Maeda T, Park SJ, Choi J, Andreoli M, Darwish T, Savage DJ, Kim KB, Gupta J, Shen J, Shirai K, Choi A, Pai L, Vazquez VL, Moser J, Amaral T, Hernandez Aya LF, Lutzky J, Najjar YG, Costello CM, Mangold AR, Bhatia S, Gibney GT, Farma JM, Daniels GA, Sosman J, Chandra S, Mangla A, Bollin K, Possik PA, Robles-Espinoza CD, Ito F, and In GK
- Subjects
- Humans, Male, Female, Middle Aged, Retrospective Studies, Aged, Adult, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Antineoplastic Combined Chemotherapy Protocols adverse effects, Progression-Free Survival, Neoplasm Staging, Skin Neoplasms drug therapy, Skin Neoplasms pathology, Skin Neoplasms immunology, Skin Neoplasms mortality, Melanoma drug therapy, Melanoma mortality, Melanoma immunology, Melanoma pathology, CTLA-4 Antigen antagonists & inhibitors, CTLA-4 Antigen immunology, Programmed Cell Death 1 Receptor antagonists & inhibitors, Immune Checkpoint Inhibitors adverse effects, Immune Checkpoint Inhibitors administration & dosage, Immune Checkpoint Inhibitors therapeutic use
- Abstract
Background: Combination immune checkpoint blockade targeting programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte associated protein 4 (CTLA-4) leads to high response rates and improved survival in patients with advanced cutaneous melanoma (CM). Less is known about the efficacy of this combination in acral lentiginous melanoma (ALM)., Objectives: To determine the efficacy of combination immune checkpoint blockade targeting PD-1 and CTLA-4 in a diverse, real-world population of patients with ALM., Methods: This multi-institutional retrospective study analysed patients with histologically confirmed ALM treated with a combination of PD-1 and CTLA-4 inhibitors between 2010 and 2022. The primary objective of the study was the objective response rate (ORR) as per the RECIST criteria. The secondary objectives were progression-free survival (PFS) and overall survival (OS)., Results: In total, 109 patients with advanced ALM treated with combined PD-1 and CTLA-4 blockade in any line of treatment were included. The majority of patients had stage IV disease (n = 81; 74.3%). The ORR for the entire cohort was 18.3% [95% confidence interval (CI) 11.6-26.9], with 9 (8.3%) complete and 11 (10.1%) partial responses. A further 22 patients (20.2%) had stable disease, and the disease control rate was 38.5%. Median PFS was 4.2 months (95% CI 3.25-5.62), while median OS was 17 months (95% CI 12.4-23.1). Ninety-five patients (87.2%) had a treatment-related adverse event, with 40.4% (n = 44/109) experiencing at least one grade 3 or 4 toxicity. Elevated lactate dehydrogenase (P = 0.04), ≥ 2 lines of prior treatment (P = 0.03) and Asian ethnicity (P = 0.04) were associated with worse OS, while Hispanic/Latino ethnicity was associated with better OS (P = 0.02)., Conclusions: Combination PD-1 and CTLA-4 blockade is less effective for ALM than for CM, despite similar toxicity. In particular, Asian patients appear to derive less benefit from this regimen. Novel treatment approaches are needed for this rare melanoma subtype., Competing Interests: Conflicts of interest: Unrelated to this work, C.M.C. has worked as the Principal Investigator with DeepX Health on melanoma diagnostic imaging technology. The funding was paid to his institution. G.K.I. is on advisory boards for BMS, Merck, Regeneron, Array, Castle Biosciences, Sanofi, Replimune and Pfizer. Institutional research support funds were provided by Regeneron, Array, Idera, Replimune, Xencor, InstilBio, Pfizer and Checkmate Pharmaceuticals. K.B.K. has received honoraria for serving as a speaker and member of an advisory board for Bristol Myers Squibb. He is also an Editorial Board Member/Editor-in-Chief/Associate Editor/Guest Editor for Melanoma Management and was not involved in the editorial review or the decision to publish this article. A.R.M. has received grants/research fundings from Kyowa, Miragen, Regeneron, Corbus, Sun Pharma, Incyte, Pfizer Inc, Merck & Co., Priovant Therapeutics, Eli Lilly, Elorac, Novartis, Janssen, Soligenix, Argenx, Palvella and AbbVie; and has served as a consultant for Kyowa, Eli Lilly, Momenta, UCB, Regeneron, Incyte, PHELEC, Soligenix, Clarivate, Argenx, Janssen, Bristol Myers Squibb, Boehringer Ingelheim and Pfizer. He has two provisional intellectual property (IP)/patents and one filed IP/patent (‘Methods and materials for assessing and treating cutaneous squamous cell carcinoma’ provisional 63-423254; ‘Use of oral Jaki in lichen planus’ provisional 63/453,065; and ‘Topical ruxolitinib in lichen planus’ wo2022072814a1, respectively). Y.G.N. is on the consulting/advisory board for Merck, BMS, Pfizer, Immunocore, Mallinkrodt, InterVenn Bio and Novartis. She is a speaker for Immunocore and Pfizer. The other authors declare no conflicts of interest., (© The Author(s) 2024. Published by Oxford University Press on behalf of British Association of Dermatologists. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
- Published
- 2025
- Full Text
- View/download PDF